IMRX IMMUNEERING CORP revenue, earnings and financials
For the quarter ended June 30, 2026, IMMUNEERING CORP reported revenue of n/a, net income of −$17.3M and diluted EPS of −$0.27; for the fiscal year ended December 2025 revenue was n/a.
IMRX annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income −$59.4M, net income −$56.0M (margin n/a), EPS −$1.27
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$64.1M, net income −$61.0M (margin n/a), EPS −$2.04
- Fiscal year ended Dec 2023: revenue $0, gross profit $0, operating income −$58.4M, net income −$53.5M (margin n/a), EPS −$1.88
- Fiscal year ended Dec 2022: revenue $317K, gross profit $159K, operating income −$51.7M, net income −$50.5M (margin -15937.3%), EPS −$1.91
- Fiscal year ended Dec 2021: revenue $2.08M, gross profit $927K, operating income −$33.9M, net income −$33.5M (margin -1612.3%), EPS −$2.46
IMRX quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$17.3M, EPS −$0.27
- Quarter ended Mar 31, 2026: revenue n/a, net income −$13.5M, EPS −$0.21
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$11.6M, EPS −$0.07
- Quarter ended Sep 30, 2025: revenue n/a, net income −$15.0M, EPS −$0.38
- Quarter ended Jun 30, 2025: revenue n/a, net income −$14.4M, EPS −$0.40
- Quarter ended Mar 31, 2025: revenue n/a, net income −$15.0M, EPS −$0.42
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income −$18.1M, EPS −$0.59
- Quarter ended Sep 30, 2024: revenue n/a, net income −$14.6M, EPS −$0.49
- Quarter ended Jun 30, 2024: revenue n/a, net income −$14.1M, EPS −$0.47
- Quarter ended Mar 31, 2024: revenue n/a, net income −$14.3M, EPS −$0.49
- Quarter ended Dec 31, 2023 (from the annual report): revenue $0 (down 100.0% year over year), net income −$15.1M, EPS −$0.51
- Quarter ended Sep 30, 2023: revenue $0 (down 100.0% year over year), net income −$12.6M, EPS −$0.43
- Quarter ended Jun 30, 2023: revenue $0 (down 100.0% year over year), net income −$12.2M, EPS −$0.43
- Quarter ended Mar 31, 2023: revenue $0 (down 100.0% year over year), net income −$13.6M, EPS −$0.51
- Quarter ended Dec 31, 2022 (from the annual report): revenue $455 (down 99.8% year over year), net income −$13.2M, EPS −$0.49
- Quarter ended Sep 30, 2022: revenue $38.4K (down 92.0% year over year), net income −$12.8M, EPS −$0.49
- Quarter ended Jun 30, 2022: revenue $94.4K (down 85.7% year over year), net income −$11.5M, EPS −$0.44
- Quarter ended Mar 31, 2022: revenue $184K (down 75.4% year over year), net income −$12.9M, EPS −$0.49
- Quarter ended Dec 31, 2021 (from the annual report): revenue $190K, net income −$10.8M, EPS $0.88
- Quarter ended Sep 30, 2021: revenue $482K, net income −$8.53M, EPS −$0.47
IMRX cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$45.3M, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$55.0M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$49.0M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$44.1M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$30.9M, share buybacks n/a
IMRX balance sheet
- Jun 30, 2026: cash $41.3M, total assets $202M, total liabilities $11.3M, shareholders' equity $191M
- Mar 31, 2026: cash $47.3M, total assets $215M, total liabilities $8.29M, shareholders' equity $207M
- Dec 31, 2025: cash $129M, total assets $232M, total liabilities $13.5M, shareholders' equity $218M
- Sep 30, 2025: cash $228M, total assets $241M, total liabilities $13.1M, shareholders' equity $228M
- Jun 30, 2025: cash $26.4M, total assets $40.1M, total liabilities $11.1M, shareholders' equity $28.9M
- Mar 31, 2025: cash $35.9M, total assets $50.7M, total liabilities $8.84M, shareholders' equity $41.8M
- Dec 31, 2024: cash $36.1M, total assets $52.7M, total liabilities $11.3M, shareholders' equity $41.4M
- Sep 30, 2024: cash $45.2M, total assets $68.6M, total liabilities $10.8M, shareholders' equity $57.7M
Is IMRX profitable?
No. IMMUNEERING CORP lost $57.3M over the last four quarters.
What is IMRX's EPS?
Diluted earnings per share over the last four quarters were −$0.93; −$0.27 in the latest quarter.